Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Weight-loss injections like semaglutide are trending in India, but are they safe? Know the science, risks, and why expert ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

To confirm the hypothesis that concurrent menopause hormone therapy enhances the effectiveness of tirzepatide for weight loss in postmenopausal women, researchers conducted a real-world study using ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...